Pharmaceutical Technology

APRIL 4, 2023

The combination therapy can be used to treat la/mUC patients who do not qualify for cisplatin-containing chemotherapy. Merck stated that the regulatory approval represents the first of its kind received by an anti-PD-1 therapy in combination with an antibody-drug conjugate for use in targeted patients in the US.

Antibody 130

Antibody Containment Clinical Development Trials 130

Worldwide Clinical Trials

SEPTEMBER 29, 2022

Ensuring a seamless transition from preclinical to clinical stages in large molecule bioanalysis will help you reach crucial trial milestones on time and within budget. For studies of humanized therapeutics (monoclonal antibodies [mAb], fusion protein, antibody-drug conjugates [ADC], bispecific antibodies, etc.),

Reagent 130

Reagent Clinical Trials Clinical Trials Antibody 130

Pharmaceutical Technology

AUGUST 5, 2022

According to GlobalData’s Pharma Intelligence Center, there are only six drugs in active development for CJD, of which only one has been in clinical trials. Since research needs to be done under containment conditions, samples cannot be moved across different facilities, he explains.

Drugs 299

Drugs Protein Vaccine Vaccination 299

Pharmaceutical Technology

FEBRUARY 25, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates.

Antibody 100

Antibody Engineer Development Drugs 100

Pharmaceutical Technology

FEBRUARY 25, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates.

Antibody 100

Antibody Engineer Development Drugs 100

Pharmaceutical Technology

FEBRUARY 25, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates.

Antibody 100

Antibody Engineer Development Drugs 100

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. Clinical data show strong neutralising antibody responses against Omicron BA.1, 1 subvariant of Omicron.

Protein 122

Protein Immune Response Vaccine Vaccination 122

Pharmaceutical Technology

MARCH 28, 2023

On March 27, researchers presented new interim results from the Phase III RUBY clinical trial that could indicate a new standard of care for endometrial cancer treatment. GSK’s trial evaluated the programmed death receptor-1 (PD-1)-blocking antibody Jemperli (dostarlimab).

DNA 130

DNA Clinical Trials Clinical Trials Trials 130

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). log 10 copies/mL for combined doses).

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About Cantargia.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

pharmaphorum

OCTOBER 2, 2020

Confirming press reports, the EMA said that large scale clinical trials from the vaccine codenamed AZD1222 involving several thousands of people are ongoing and results will become available over “the coming weeks and months”. AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech.

Regulation 105

Regulation Vaccination Vaccine Protein 105

Pharmaceutical Technology

SEPTEMBER 8, 2022

The list includes providers of development services, biologics management supply chain solutions, clinical trial services, commercial and logistics services, as well as packaging, labelling and distributing services for biologics.

Gene 100

Gene Marketing Vaccination Vaccine 100

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As

Antibody 52

Antibody Vaccine Vaccination In-Vitro 52

Scienmag

OCTOBER 16, 2020

The blood of recovered patients contains antibodies that act against the coronavirus. While plasma hasn’t yet shown a benefit in randomized trials, some […].

Antibody 40

Antibody Containment Trials 40

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccine Vaccination Containment 52

Camargo

NOVEMBER 29, 2021

Like with small molecules, clinical trials of biologics are designed to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy. Essentially, a biologic is a product that is produced from living organisms or that contains components of living organisms. Monoclonal antibodies (mAbs). Growth factors.

Development 180

Development Protein Production Hormones 180

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif. Reese , M.D.,

Antibody 52

Antibody Manufacturing Production Sales 52

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Camargo

DECEMBER 13, 2021

Like with small molecules, clinical trials of biologics are designed to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy. Bispecific antibodies, antibody-drug conjugates, and gene therapies all have their own specific features that must be taken into account. Product Type-Specific Analysis.

Development 161

Development Production Immune Response Licensing 161

pharmaphorum

JANUARY 29, 2023

One of the Johnson & Johnson’s top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti. The post Trial sets up earlier use of J&J’s Carvykti in myeloma appeared first on.

Trials 64

Trials Sales Antibody Clinical Trials 64

XTalks

JUNE 16, 2021

Novavax shared the latest data from its ongoing late-stage COVID-19 vaccine trial, which shows that its yet-to-be authorized shot provides 100 percent protection against moderate and severe disease and has an overall efficacy of 90.4 Related: Latest Data from Novavax COVID-19 Vaccine Trial Involving B.1.351

Vaccination 98

Vaccination Vaccine Protein Trials 98

pharmaphorum

JANUARY 19, 2022

Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial. Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system. The post Sugemalimab plus chemo boosts lung cancer survival, trial reveals appeared first on.

Trials 59

Trials Containment Protein Antibody 59

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

XTalks

DECEMBER 14, 2021

The vaccine successfully boosted HA antibody titers against all strains 29 days after vaccination with all of the doses evaluated in both young and older adults. Antibody levels against the A strains were higher than the B subtypes. First Trial Results for First mRNA Influenza Vaccine.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

pharmaphorum

AUGUST 16, 2020

ChAdOx1 – which is in large-scale phase 2/3 trials – was licensed by AZ in April and renamed AZD1222, and should be ready for first deliveries before the end of the year. It will be provided on a no-profit basis while the pandemic is ongoing. Those deals cover 200 million doses of J&J’s Ad26.COV2.S

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

XTalks

APRIL 23, 2021

Dostarlimab is a programmed death receptor-1 (PD-1) blocking antibody that targets the PD-1/PD-L1 pathway to block its inhibition of T cell function, allowing the immune cells to seek out and destroy cancer cells. Dostarlimab and the GARNET Trial. percent with a complete response (CR) rate (disappearance of tumor) of 12.7

FDA Approval 105

FDA Approval Trials Antibody DNA 105

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Clinical Trials Medicine Trials 52

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. TARRYTOWN, N.Y. , 28, 2020 /PRNewswire/ — . Regeneron has shared these results with the U.S. Regeneron Pharmaceuticals, Inc.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

The treatment is based on the Grifols immunoglobulin Gamunex®-C, and contains anti-SARS-COV-2 polyclonal antibodies from plasma donors who have recovered from COVID-19. It could also help contain outbreaks in places where the vaccination hasn’t begun or is still underway. BARCELONA, Spain , Jan.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Antibody 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. The full set of results will be published once the complete Phase 1/2a trial data are available.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

JANUARY 9, 2024

Clinical Trials for Thyroid Conditions New treatments are being evaluated in clinical studies for various thyroid conditions, including thyroid cancer. It is currently being studied as a monotherapy in radioiodine – refractory, differentiated thyroid cancer in the Phase III COSMIC-311 trial , which has shown promising results so far.

Hormones 105

Hormones Antibody Trials Production 105